Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Explore this paper's citation graph
Summary
The ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor is reported.
- Type
- article
- Published
- 2006-10-06
- Cited by
- 2,733
- References
- 28
- Access
- Open access
- OpenAlex
- https://openalex.org/W2094652659
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:24524531
Keywords
Adoptive cell transfer, Genetically engineered, Genetically modified organism, Melanoma, Medicine
References
- Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines
- Transfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions
- T-cell-receptor gene therapy
- Cancer Immunotherapy: A Treatment for the Masses
- Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.
- T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates
- Targeting tumours with genetically enhanced T lymphocytes
- Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.
- A new era for cancer immunotherapy based on the genes that encode cancer antigens.
- The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells.
- A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
- Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells
- Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR
- Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
- High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens
- New guidelines to evaluate the response to treatment in solid tumors
- Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
- How T cells 'see' antigen
- Immunity
Cited by
- Cloning CD8⁺ cytolytic T lymphocytes.
- The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer.
- Medulloblastomas Expressing IL13Rα2 are Targets for IL13-zetakine+ Cytolytic T Cells
- Overexpression of program death‐1 in T cells has mild impact on allograft survival
- Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation
- In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method
- Arthritis gene therapy's first death
- T Cell Receptor Gene Therapy for Cancer
- Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.
- Development of targeted gene delivery vectors to assess cardiac overexpresion of ACE2 in vivo
- Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways.
- Targeting Bcl-2 in CLL: cui bono?
- Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection
- Nitrosylhemoglobin in photodynamically stressed human tumors growing in nude mice.
- A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model
- Cancer immunotherapy: accomplishments to date and future promise.
- CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy
- High-throughput identification of antigen-specific TCRs by TCR gene capture
- Computational Design of the Affinity and Specificity of a Therapeutic T Cell Receptor
- The targeting of immunosuppressive mechanisms in hematological malignancies
Related papers
- Regulations on Genetically Engineered Animals; Publications from FDA, APHIS Released; Recombinant Rabies Vaccine to Be Tested; Herbicide-Tolerant Soybeans Deregulated; G8 Nations Want Greater Use of Genetically Engineered Plants; France May Be Fined over Laws on Genetically Engineered Crops; Concern About Nanotechnology Effects on Bacteria
- The Australian public's perception of genetically-engineered foods
- Genetically Engineered Organisms: Progress or Poison
- Guidance Document for the risk assessment of genetically modified plants containing stacked transformation events by the Scientific Panel on Genetically Modified Organisms (GMO).
- Daily briefing: Fruit flies genetically engineered for 'virgin birth'.
- The allergenicity of genetically modified foods from genetically engineered crops: A narrative and systematic review.
- Hurdles Associated with the Translational Use of Genetically Modified Cells
- Genetically Modified Planet: Environmental Impacts of Genetically Engineered Plants